Studi In Vitro dan In Silico Senyawa Analog Kurkumin 2,6-Bis(2'-Etoksibenziliden)-Sikloheksanon sebagai Penghambat Angiotensin Converting Enzyme
NATASIA PUTRI ANDRIANA, Dr. apt. Rumiyati, M.Si.; apt. Navista Sri Octa Ujiantari, M.Sc., Ph.D.
2024 | Skripsi | FARMASI
Hypertension is one of the diseases with the highest prevalence in Indonesia. Hypertension is common and has the potential to become a serious problem if not treated immediately, hence it is known as the silent killer. Since ancient times, people have empirically used turmeric rhizomes (Curcuma longa L.) as traditional medicine. Turmeric has curcumin as the main active compound, which has antioxidant, antibacterial, anti-inflammatory and anti-proliferative activity. Curcumin has also been reported to prevent the development of hypertension by inhibiting ACE activity. The development of curcumin analogues was carried out to utilize curcumin as a medicine and increase its bioavailability. Curcumin analogues are reported to have potential as ACE inhibitor agents, especially those with electron donating groups as substituents. The compound 2,6-Bis(2'-Etoxybenzylidene)-Cyclohexanone (A145) is a curcumin analogue that has an ethoxy substituent, which is an electron donating group. This research was conducted to determine the activity of compound A145 as an ACE inhibitor.
This research was carried out with an in vitro study using the Angiotensin I Converting Enzyme (ACE) Activity Assay Kit (Fluorometric) (Sigma-Aldrich) to see the ACE inhibition activity of A145 and continued with an in silico study through molecular docking in MOE to see the interaction between A145 with ACE.
In vitro study of ACE inhibitory activity by A145 at a concentration of 50 ?M (% inhibition = 81.57 ± 2.32%) showed results that were not significantly different from ramipril (% inhibition = 71.06 ± 1.18). The docking of the test compound to ACE is adjusted to the results of the docking protocol validation (site pocket, Alpha PMI placement, refinement induced fit, and scoring function London-dG). Molecular docking results show that the test compound has hydrogen bonds with His353 and hydrophobic interactions with Tyr523, Ala354, and Ser353 on the ACE receptor.
Kata Kunci : kurkumin, analog kurkumin, ACE inhibitor, molecular docking